DrugPatentWatch Database Preview

DURYSTA Drug Profile

Email this page to a colleague

« Back to Dashboard

Which patents cover Durysta, and what generic alternatives are available?

Durysta is a drug marketed by Allergan Inc and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and sixty-one patent family members in thirty-one countries.

The generic ingredient in DURYSTA is bimatoprost. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Durysta

A generic version of DURYSTA was approved as bimatoprost by APOTEX INC on December 1^st, 2014.

Summary for DURYSTA

International Patents:	161
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for DURYSTA
What excipients (inactive ingredients) are in DURYSTA?	DURYSTA excipients list
DailyMed Link:	DURYSTA at DailyMed

See drug prices for DURYSTA

Pharmacology for DURYSTA

Drug Class

Prostaglandin Analog

ATC Classes for DURYSTA

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for DURYSTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes			Y	Y
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes			Y
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes

Expired US Patents for DURYSTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan Inc	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020

International Patents for DURYSTA

Country	Patent Number	Estimated Expiration
Japan	2004210798
New Zealand	549516
Poland	2558081
European Patent Office	3062775
Israel	268976
Australia	2006201271

Supplementary Protection Certificates for DURYSTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	SPC/GB02/035	United Kingdom		PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716	02C0033	France		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716	C300099	Netherlands		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308